Results 11 to 20 of about 96,322 (259)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer [PDF]

, 2022
EML4-ALK is an oncogenic fusion protein that accounts for approximately 5% of NSCLC cases. Targeted inhibitors of ALK are the standard of care treatment, often leading to a good initial response.
Laura O'Regan (35351), Sam Khan (13264131), Savvas Papageorgiou (13308312), Sarah L Pashley (13308315), Andrew M Fry (9097310), Richard Bayliss (610319)   +5 more
core   +8 more sources

T cells specific to multiple Bet v 1 peptides are highly cross-reactive toward the corresponding peptides from the homologous group of tree pollens

Frontiers in Immunology, 2023
BackgroundAllergens from Fagales trees frequently cause spring allergy in Europe, North America, and some parts of Asia. The definition of the birch homologous group, which includes birch (Bet v), oak (Que a), alder (Aln g), hazel (Cor a), hornbeam (Car ...
Gitte Lund, Lars Harder Christensen, Jacob Ihlemann, Peter Sejer Andersen, Erik Wambre, Peter Adler Würtzen, Shashank Gupta   +6 more
doaj   +1 more source

A practical guide to prescribing sublingual immunotherapy tablets in North America for pediatric allergic rhinoconjunctivitis: an injection-free allergy immunotherapy option

Frontiers in Pediatrics, 2023
Allergic rhinoconjunctivitis (ARC) is a common disease that affects individuals of all ages. Pediatricians may be the first (and only) point of care for children with ARC.
Michael Blaiss, Lawrence DuBuske, Hendrik Nolte, Morten Opstrup, Karen Rance   +4 more
doaj   +1 more source

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Clinical and Translational Allergy, 2022
Background This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy‐tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective.
Mette Bøgelund, Ana Rosado Ingelmo, Jose María Ausín Ruiz, Adolfo Galán Vivó, Henrik Brandi, Mikkel Hasse Pedersen, Anne Sofie Ledgaard Loftager, Mark Aagren   +7 more
doaj   +1 more source

Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets

Current Therapeutic Research, 2022
: Background: Sublingual allergy immunotherapy tablets (SLIT-tablets) provide a well-tolerated and clinically efficacious treatment for allergic disease such as allergic rhinitis and allergic asthma. In SLIT, uptake of allergen by immune-competent cells
Takashi Yamamoto, PhD, Katsuyo Ohashi-Doi, PhD, Hiroki Matsuhara, BSc, Loes Verhoog, MSc, Morten Lindholm, PhD, Simon Lawton, MD, Kaare Lund, PhD   +6 more
doaj   +1 more source

Low-Concentration Enhancement Effect: Enabling Sensitive Detection of EML4-ALK Variants via Multiplex RT-MIRA. [PDF]

J Clin Lab Anal
This study developed an optimized multiplex RT‐MIRA assay for the simultaneous detection of EML4‐ALK variants, achieving single‐copy sensitivity. Unexpectedly, during the development of the reaction system, we discovered a “low‐concentration enhancement effect,” where reducing primer or probe concentrations within a specific range markedly improved ...
Ren XD, Luo XY, Li JM, Sun XG, Lv J, Xiao HL, Wang QS, Wang H, Wang CY, Li HZ, Huang Q.   +10 more
europepmc   +2 more sources

ITULAZAX® versus Alutard SQ® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective

Clinical and Translational Allergy, 2022
Background and aims Allergic rhinitis (AR) is an inflammatory disorder triggered by an allergic immune response to inhaled allergens. Birch pollen is the major allergenic tree pollen in parts of Europe.
Steen M. Rønborg, Tobias Sydendal Grand, Henrik Brandi, Richard F. Pollock   +3 more
doaj   +1 more source

Correction to: The impact of perennial allergic rhinitis with/without allergic asthma on sleep, work and activity level

Allergy, Asthma & Clinical Immunology, 2020
The first and corresponding author was unfortunately presented as Mercedes Rodriguez Romano. The correct author name is Mercedes Romano.
Mercedes Romano, Stephanie James, Emily Farrington, Richard Perry, Lisa Elliott   +4 more
doaj   +1 more source

Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.

The Lancet Regional Health. Europe, 2022
Summary: Background: Allergen immunotherapy (AIT) is the only causal treatment for respiratory allergy. Long-term real-life effectiveness of AIT remains to be demonstrated beyond the evidence from randomised controlled trials (RCTs).
Benedikt Fritzsching, Marco Contoli, Celeste Porsbjerg, Sarah Buchs, Julie Rask Larsen, Lisa Elliott, Mercedes Romano Rodriguez, Nick Freemantle   +7 more
doaj   +1 more source

The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases

Allergology International, 2018
Allergy immunotherapy (AIT) is a treatment option for respiratory allergy that is complementary to pharmacotherapy, with a distinct mechanism of action.
Hendrik Nolte, Jennifer Maloney
doaj   +1 more source